Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 3.1% – What’s Next?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was down 3.1% during mid-day trading on Thursday . The company traded as low as $5.81 and last traded at $5.85. Approximately 1,291,507 shares were traded during mid-day trading, a decline of 78% from the average daily volume of 5,819,204 shares. The stock had previously closed at $6.04.

Analysts Set New Price Targets

RXRX has been the topic of several recent research reports. Jefferies Financial Group cut their price objective on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research report on Tuesday, September 3rd. Leerink Partners cut their price objective on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a research report on Tuesday, September 3rd. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Wednesday. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $9.25.

Recursion Pharmaceuticals Stock Performance

The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The firm has a fifty day simple moving average of $6.62 and a 200 day simple moving average of $7.51.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company had revenue of $26.08 million for the quarter, compared to analyst estimates of $12.62 million. During the same quarter last year, the business earned ($0.43) EPS. The company’s revenue for the quarter was up 147.6% on a year-over-year basis. On average, sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Insider Transactions at Recursion Pharmaceuticals

In other news, COO Tina Marriott sold 6,000 shares of the firm’s stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $7.56, for a total value of $45,360.00. Following the sale, the chief operating officer now owns 521,138 shares in the company, valued at approximately $3,939,803.28. This trade represents a 1.14 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Blake Borgeson sold 11,447 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $6.27, for a total transaction of $71,772.69. Following the completion of the sale, the director now owns 7,121,322 shares in the company, valued at approximately $44,650,688.94. The trade was a 0.16 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 171,682 shares of company stock worth $1,133,471. Insiders own 15.75% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of RXRX. Allspring Global Investments Holdings LLC bought a new position in Recursion Pharmaceuticals in the third quarter worth $25,000. Farther Finance Advisors LLC lifted its holdings in shares of Recursion Pharmaceuticals by 176.9% during the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock valued at $42,000 after acquiring an additional 4,091 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Recursion Pharmaceuticals by 1,588.4% during the second quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock valued at $48,000 after acquiring an additional 6,036 shares during the period. KBC Group NV lifted its holdings in shares of Recursion Pharmaceuticals by 79.9% during the third quarter. KBC Group NV now owns 7,602 shares of the company’s stock valued at $50,000 after acquiring an additional 3,377 shares during the period. Finally, Amalgamated Bank raised its holdings in shares of Recursion Pharmaceuticals by 52.4% in the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after buying an additional 2,459 shares during the last quarter. 89.06% of the stock is owned by institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.